OBJECTIVE: Chromosomal loss within the region of 18q and loss of SMAD4 expression have been reported to be frequent somatic events during colorectal cancer tumour progression; however, their associations with age at onset have not been widely studied. METHOD: We analysed 109 tumours from a population-based case-family study based on colorectal cancers diagnosed before the age of 45 years. These patients with early-onset colorectal cancer had been previously screened for germ-line mismatch repair gene mutations, microsatellite instability (that included the mononucleotide repeat in TGFbetaRII) and somatic k-ras mutations. We measured SMAD4 protein expression using immunohistochemistry and SMAD4 copy number using quantitative real-time PCR. RESULTS: Loss of SMAD4 protein expression was observed in 27/109 (25%) of cancers tested and was more commonly observed in rectal tumours (15/41, 36%) when compared with tumours arising in the colon (11/66, 17%) (P = 0.04). There was no association between SMAD4 protein expression and TGFbetaR11 mutation status, SMAD4 copy number, family history, MSI status, tumour stage or grade. CONCLUSION: Loss of SMAD4 expression is a common feature of early-onset colorectal tumours as it is in colorectal cancers diagnosed in other age-groups. Taken together, the molecular pathways (genetic and epigenetic) now known to be involved in early-onset colorectal cancer only explain a small proportion of the disease and require further exploration.
OBJECTIVE: Chromosomal loss within the region of 18q and loss of SMAD4 expression have been reported to be frequent somatic events during colorectal cancer tumour progression; however, their associations with age at onset have not been widely studied. METHOD: We analysed 109 tumours from a population-based case-family study based on colorectal cancers diagnosed before the age of 45 years. These patients with early-onset colorectal cancer had been previously screened for germ-line mismatch repair gene mutations, microsatellite instability (that included the mononucleotide repeat in TGFbetaRII) and somatic k-ras mutations. We measured SMAD4 protein expression using immunohistochemistry and SMAD4 copy number using quantitative real-time PCR. RESULTS: Loss of SMAD4 protein expression was observed in 27/109 (25%) of cancers tested and was more commonly observed in rectal tumours (15/41, 36%) when compared with tumours arising in the colon (11/66, 17%) (P = 0.04). There was no association between SMAD4 protein expression and TGFbetaR11 mutation status, SMAD4 copy number, family history, MSI status, tumour stage or grade. CONCLUSION: Loss of SMAD4 expression is a common feature of early-onset colorectal tumours as it is in colorectal cancers diagnosed in other age-groups. Taken together, the molecular pathways (genetic and epigenetic) now known to be involved in early-onset colorectal cancer only explain a small proportion of the disease and require further exploration.
Authors: E Montgomery; M Goggins; S Zhou; P Argani; R Wilentz; M Kaushal; S Booker; K Romans; P Bhargava; R Hruban; S Kern Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: J E Armes; L Trute; D White; M C Southey; F Hammet; A Tesoriero; A M Hutchins; G S Dite; M R McCredie; G G Giles; J L Hopper; D J Venter Journal: Cancer Res Date: 1999-04-15 Impact factor: 12.701
Authors: Mark A Jenkins; Laura Baglietto; Gillian S Dite; Damien J Jolley; Melissa C Southey; Jonathan Whitty; Leeanne J Mead; D James B St John; Finlay A Macrae; D Timothy Bishop; Deon J Venter; Graham G Giles; John L Hopper Journal: Int J Cancer Date: 2002-11-10 Impact factor: 7.396
Authors: Kathryn Alsop; Leeanne Mead; Letitia D Smith; Simon G Royce; Andrea A Tesoriero; Joanne P Young; Andrew Haydon; Garry Grubb; Graham G Giles; Mark A Jenkins; John L Hopper; Melissa C Southey Journal: Eur J Cancer Date: 2006-06-09 Impact factor: 9.162
Authors: R E Wilentz; C A Iacobuzio-Donahue; P Argani; D M McCarthy; J L Parsons; C J Yeo; S E Kern; R H Hruban Journal: Cancer Res Date: 2000-04-01 Impact factor: 12.701
Authors: I Seshimo; H Yamamoto; H Mishima; A Kurata; R Suzuki; K Ezumi; I Takemasa; M Ikeda; T Fukushima; T Tsujinaka; M Sekimoto; N Kikkawa; S Takenoshita; M Monden Journal: J Exp Clin Cancer Res Date: 2006-09
Authors: R Salovaara; S Roth; A Loukola; V Launonen; P Sistonen; E Avizienyte; P Kristo; H Järvinen; S Souchelnytskyi; M Sarlomo-Rikala; L A Aaltonen Journal: Gut Date: 2002-07 Impact factor: 23.059
Authors: Leeanne J Mead; Mark A Jenkins; Joanne Young; Simon G Royce; Letitia Smith; D James B St John; Finlay Macrae; Graham G Giles; John L Hopper; Melissa C Southey Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: J L Boulay; G Mild; A Lowy; J Reuter; M Lagrange; L Terracciano; U Laffer; R Herrmann; C Rochlitz Journal: Br J Cancer Date: 2002-09-09 Impact factor: 7.640
Authors: Ian W Saunders; Jason Ross; Finlay Macrae; Graeme P Young; Ignacio Blanco; Jesper Brohede; Glenn Brown; Diana Brookes; Trevor Lockett; Peter L Molloy; Victor Moreno; Gabriel Capella; Garry N Hannan Journal: Eur J Hum Genet Date: 2011-08-10 Impact factor: 4.246
Authors: Xu Jia; Chandrakumar Shanmugam; Ravi K Paluri; Nirag C Jhala; Michael P Behring; Venkat R Katkoori; Shajan P Sugandha; Sejong Bae; Temesgen Samuel; Upender Manne Journal: Oncotarget Date: 2017-03-21